Patentapplication WO2015024664 by CureVac discloses developmentof a mRNA-based personalized cancer vaccine encoding prostate cancer-associatedantigens, prostate-specific antigen), PSMA (prostate-specific membraneantigen), PSCA (prostate stem cell antigen), STEAP (six transmembraneepithelial antigen of the prostate), MUC1 (mucin 1) and PAP (prostaticacid phosphatase) for treating prostate cancer. The gene discussed is PSCA; the disease is prostate carcinoma.